OR WAIT null SECS
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
July 12, 2021
UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals.
July 09, 2021
Tezepelumab, being developed by AstraZeneca in collaboration with Amgen, reduced asthma exacerbations in Phase II and III clinical trials.
July 03, 2021
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.
Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.
Container and equipment innovations expand applications.
July 02, 2021
Vaccines define the path to putting the pandemic in the rear-view mirror.
June 30, 2021
Amgen’s greenfield facility near Columbus, Ohio to assemble and package vials and syringes is expected to be operational by 2024.
Modified-release dosage forms present new opportunities for drug developers and can help overcome challenges, such as short biological half-life or poor bioavailability due to degradation in the stomach.
June 23, 2021
The European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022.
June 22, 2021
EMA's recent positive opinion for a recombinant vaccine for rabbits developed using Algenex’s proprietary and patent protected Baculovirus vector-mediated expression platform, CrisBio, should push the full commercialization of the platform forward.